tyrosine kinase inhibitor (Hughes Institute)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Nametyrosine kinase inhibitor (Hughes Institute)
Drug Alias Nameanticancer therapeutic (Parker Hughes)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLymphomaLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesHughes Institute
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHughes Institute
Active IndicationsN/A
Inactive IndicationsLymphomaLeukemia

Other Information

ATC CodeN/A
Related LinksN/A